Non-randomized, prospective, non-controlled study of changes of lipid parameters after introduction of evolocumab in patients with heterozygous familial hypercholesterolemia under LDL-apheresis therapy.
Phase of Trial: Phase II
Latest Information Update: 12 Jun 2017
At a glance
- Drugs Evolocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- 08 Jun 2017 Status changed from recruiting to discontinued.
- 22 Jun 2016 New trial record